GlassScriptPhysician profile
Robert Drake Bolen
NPI 1568751717
$22,649.87
in general payments reported to CMS, 2019-2025
77 companies · $4,410 in 2025
The $4,410 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,076 · 2020: $1,665 · 2021: $2,803 · 2022: $3,661 · 2023: $3,675 · 2024: $4,360 · 2025: $4,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $175 · Education: $8.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,260.64 |
| Consulting Fee | $175.00 |
| Education | $8.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,764.34 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Biogen, INC. | $1,510.60 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Abbvie INC. | $1,468.55 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Sk Life Science, INC. | $1,286.13 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,206.59 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Acadia Pharmaceuticals INC | $833.09 | 2019-2025 | Nuplazid |
| Eisai INC. | $788.58 | 2019-2025 | |
| Lilly USA, LLC | $783.63 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Novartis Pharmaceuticals Corporation | $724.61 | 2019-2025 | |
| Amgen INC. | $716.88 | 2019-2025 | Uplizna, Aimovig |
| Emd Serono, INC. | $706.47 | 2019-2025 | Mavenclad |
| Mdd US Operations, LLC | $663.86 | 2019-2025 | Gocovri, Gocovri |
| Genzyme Corporation | $660.46 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $653.98 | 2021-2025 | Ingrezza, Ongentys |
| Genentech USA, INC. | $570.95 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bolen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.